Thoracic aortitis and aortic dissection following pegfilgrastim administration

Eur J Cardiothorac Surg. 2017 Nov 1;52(5):993-994. doi: 10.1093/ejcts/ezx165.

Abstract

The patient was a 67-year-old woman with a history of advanced lung adenocarcinoma. Eight days after pegfilgrastim administration, her computed tomography scan revealed thickened bilateral common carotid arteries and thoracic aorta, which led to the diagnosis of pegfilgrastim-associated aortitis. Thirty-six days after pegfilgrastim administration, asymptomatic Stanford type B aortic dissection was detected. Her serum biomarker analysis suggested that interleukin-6 might be involved in the pathogenesis. Physicians should be aware of these adverse effects of filgrastim.

Keywords: Aortic dissection; Aortitis; Pegfilgrastim.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma of Lung
  • Aged
  • Aortic Dissection* / chemically induced
  • Aortic Dissection* / diagnostic imaging
  • Aortitis* / chemically induced
  • Aortitis* / diagnostic imaging
  • Female
  • Filgrastim / adverse effects*
  • Filgrastim / therapeutic use
  • Hematologic Agents / adverse effects*
  • Hematologic Agents / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy
  • Polyethylene Glycols / adverse effects*
  • Polyethylene Glycols / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Hematologic Agents
  • pegfilgrastim
  • Polyethylene Glycols
  • Filgrastim